Every Form 4 that Corbus Pharmaceuticals Holdings, Inc. (CRBP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRBP filings page.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) director Ben Yong sold 2,000 shares of common stock on September 14, 2026 in an open-market transaction at a weighted average price of $7.84 per share, under a Rule 10b5-1 trading plan adopted on June 12, 2026. Following the sale, he held 9,383 shares in total, including 3,800 unvested RSUs subject to vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. granted its Chief Medical Officer, Nicacio Leonardo Viana, new equity awards on August 16, 2026. He received 191,676 stock options to buy common stock at an exercise price of $10.09 per share, expiring on August 16, 2036. Under the company’s 2026 Inducement Award Plan, 25% of this option vests on August 3, 2027, with the remaining 75% vesting in equal monthly installments over 36 months starting September 3, 2027. He was also granted 58,333 restricted stock units (RSUs), settling in common shares, vesting 25% on each of the first four anniversaries beginning August 16, 2027, with specified prorated vesting and forfeiture terms if his service is terminated without cause after the first vesting date.
Corbus Pharmaceuticals Holdings, Inc. Chief Business Officer Nishant C Saxena purchased 2,600 shares of common stock on 2026-08-11 at an average price of $9.6294 per share in a direct open-market or private transaction. Following this trade, his direct holdings total 77,900 shares, which the footnote states include 58,300 unvested RSUs subject to a vesting schedule. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.
Corbus Pharmaceuticals Holdings, Inc. director and Chief Executive Officer Yuval Cohen reported selling 17,000 shares of common stock on August 7, 2026 at a weighted average price of $10.0821 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Cohen holds 157,316 shares directly, including 138,049 unvested RSUs subject to vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. Chief Financial Officer Sean F. Moran reported a sale of 12,000 shares of common stock on August 7, 2026. The shares were sold at a weighted average price of $10.0809 per share under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Moran holds 84,694 shares directly, including 68,795 unvested RSUs that remain subject to their vesting schedules.
Corbus Pharmaceuticals director Winston Kung sold 2,026 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $7.9137 per share, with individual sale prices ranging from $7.71 to $7.97.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. After this transaction, Kung holds 12,140 shares directly, which includes 3,800 unvested restricted stock units subject to the grant’s vesting schedule.
Corbus Pharmaceuticals Holdings director Anne Altmeyer sold 2,412 shares of common stock in an open-market transaction at a weighted average price of $7.9137 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026.
These shares were sold in multiple trades at prices ranging from $7.71 to $7.97. After the sale, Altmeyer directly holds 7,579 shares of common stock, which includes 3,800 unvested restricted stock units that remain subject to the grant’s vesting schedule.
Corbus Pharmaceuticals Holdings, Inc. director John Kenneth Jenkins reported an open-market sale of 4,800 shares of common stock on June 10, 2026 at a weighted average price of $7.9137 per share, executed under a Rule 10b5-1 trading plan. Following this sale, he directly holds 3,833 shares of common stock and 3,800 unvested RSUs subject to the grant’s vesting schedule.
Corbus Pharmaceuticals Chief Business Officer Nishant C. Saxena bought 13,500 shares of common stock in open-market transactions. He purchased 9,000 shares at $7.58 per share on June 3 and 4,500 shares at a weighted average price of $7.33 per share on June 2, in multiple trades between $7.33 and $7.34. Following these purchases, he directly holds 75,300 common shares, including 58,300 unvested RSUs that remain subject to the grant’s vesting schedule.
Corbus Pharmaceuticals Holdings, Inc. reported that Chief Business Officer Nishant C. Saxena received new equity awards. On May 21, 2026, he was granted 58,300 restricted stock units (RSUs) that will settle in common shares, bringing his direct common stock holdings to 61,800 shares.
The RSUs vest 25% on each of the first four anniversaries beginning May 21, 2027, with partial acceleration possible if he is terminated without cause after the first vesting date. He was also granted options for 192,300 shares of common stock at an exercise price of $11.51 per share, expiring in 2036, which vest 25% on May 21, 2027 and the remaining 75% in equal monthly installments over 36 months starting June 21, 2027.
Corbus Pharmaceuticals director Winston Kung received new equity awards as part of his compensation. On May 19, 2026, he was granted 3,800 restricted stock units (RSUs), which will settle in common shares and vest 100% one year from the grant date. Following this award, his direct common stock holdings total 14,166 shares, including 8,600 unvested RSUs subject to their existing vesting schedules. On the same date, he also received stock options for 12,300 shares of common stock at an exercise price of $9.15 per share, which will also vest in full on the one-year anniversary of the grant.
Corbus Pharmaceuticals Holdings director Rachelle Suzanne Jacques received new equity awards. On May 19, 2026, she was granted 3,800 restricted stock units that will be settled in common shares and vest 100% one year after the grant date. The filing notes her common stock holdings total 11,383 shares, including 8,600 unvested RSUs subject to prior vesting schedules. She was also granted options to purchase 12,300 shares of common stock at an exercise price of $9.15 per share, which will vest 100% on the one-year anniversary of the grant, under the company’s 2024 Equity Compensation Plan.
Corbus Pharmaceuticals Holdings director John Kenneth Jenkins received new equity compensation. On May 19, 2026, he was granted 3,800 restricted stock units that will settle in common shares and vest 100% one year after the grant date. He was also granted stock options on 12,300 shares of common stock at an exercise price of $9.15 per share, which likewise vest fully on the one-year anniversary of grant under the company’s 2024 Equity Compensation Plan. Following these awards, his reported beneficial ownership is 8,633 shares of common stock, including 8,600 unvested RSUs subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. director Anne Altmeyer reported equity compensation awards. On May 19, 2026, she received 3,800 restricted stock units (RSUs) that will vest 100% one year from the grant date and be settled in common shares. She was also granted stock options on 12,300 shares of common stock at an exercise price of $9.15 per share, which will likewise vest 100% after one year. Following the RSU grant, she directly holds 9,991 shares of common stock, and the disclosure notes this amount includes 8,600 unvested RSUs subject to prior vesting schedules.
Corbus Pharmaceuticals director Ben Yong received new equity awards as part of his compensation. On May 19, he was granted 3,800 restricted stock units that will convert into common shares after they vest in full one year from the grant date.
He also received stock options for 12,300 shares of common stock at an exercise price of $9.15 per share, which will also vest 100% after one year under the company’s 2024 Equity Compensation Plan. Following these awards, he directly holds 11,383 shares of common stock, including previously reported unvested RSUs.
Corbus Pharmaceuticals director Brent Pfeiffenberger received new equity awards as part of his compensation. On May 19, 2026, he was granted 7,500 restricted stock units that will settle in common shares and vest in three equal annual installments over three years, subject to continued service. He also received options on 24,700 shares of common stock at an exercise price of $9.15 per share, expiring on May 19, 2036, which will vest on the same three-year schedule under the company’s 2024 Equity Compensation Plan. Following these awards, his reported holdings include 7,500 shares of common stock and 24,700 stock options, all held directly.
Corbus Pharmaceuticals Holdings, Inc. Chief Medical Officer Dominic Smethurst reported an open-market sale of 6,097 shares of common stock at a weighted average price of $8.2994 per share. The sale was mandated to cover tax withholding on vesting RSUs and was not a discretionary trade. After this transaction, he directly holds 89,790 shares, including 73,765 unvested RSUs that remain subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc.’s Chief Operating Officer Ian Hodgson reported an open-market sale of 847 shares of common stock at a weighted-average price of $7.383 per share. According to the disclosure, this sale was mandated as a “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units and was not a discretionary trade.
After the transaction, Hodgson directly held 51,080 shares, which the disclosure notes includes 46,362 unvested restricted stock units that continue to vest under their existing schedules.
Corbus Pharmaceuticals Holdings, Inc. Chief Financial Officer Sean F. Moran reported an open-market sale of 4,701 shares of common stock at a weighted average price of $7.783 per share. After this sale, he directly holds 96,694 shares, including 68,795 unvested restricted stock units.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and was used to cover tax withholding obligations arising from the vesting and settlement of RSUs. The sale was mandated by the company’s “sell to cover” election and is described as non-discretionary for the executive.
Corbus Pharmaceuticals Holdings, Inc. director and Chief Executive Officer Yuval Cohen reported an open-market sale of 13,871 shares of common stock at a weighted average price of $7.7826 per share on February 13, 2026.
According to the disclosure, this sale was executed under a Rule 10b5-1 trading plan adopted on March 14, 2025 and was mandated as a “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units (RSUs), rather than a discretionary trade. Following this transaction, Cohen directly owned 174,316 shares, which includes 138,049 unvested RSUs subject to their existing vesting schedules.
Corbus Pharmaceuticals’ Chief Medical Officer Dominic Smethurst sold 3,285 shares of common stock on February 3, 2026 at a weighted average price of $8.0898 per share. The shares were sold to cover tax withholding triggered by the vesting and settlement of restricted stock units under an issuer-mandated “sell to cover” arrangement, so the sale was not discretionary. After this transaction, he beneficially owns 95,887 shares, including 86,265 unvested RSUs that remain subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. Chief Operating Officer Ian Hodgson reported a mandated sale of common stock. On February 3, 2026, he sold 2,415 shares of Corbus common stock at a weighted average price of $8.0899 per share to cover tax withholding from vesting restricted stock units (RSUs).
The company required this "sell to cover" transaction for tax obligations, so it was not a discretionary trade by Hodgson. After the sale, he beneficially owned 51,927 shares, which includes 48,108 unvested RSUs that remain subject to their respective vesting schedules.
Corbus Pharmaceuticals Holdings, Inc.'s Chief Medical Officer, Dominic Smethurst, reported equity awards received on January 14, 2026. He was granted 28,365 restricted stock units (RSUs) that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027, and a pro rata acceleration feature if his service is terminated by the company without cause after the first vesting date. He also received an annual stock option award for 85,095 shares at an exercise price of $8.26 per share, vesting 25% on January 14, 2027 and the remaining 75% in equal monthly installments over 36 months starting February 14, 2027. Following these transactions, he beneficially owned 99,172 shares of common stock, including 93,065 unvested RSUs subject to their existing vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Financial Officer, Sean F. Moran. On January 14, 2026, he received 28,082 restricted stock units (RSUs) that will settle in common stock. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a pro rata acceleration feature if the company terminates his service without cause after the first vesting date. Following this grant, he beneficially owns 101,395 shares of common stock, including 85,714 unvested RSUs.
On the same date, he was also granted stock options to purchase 84,247 shares of common stock at an exercise price of $8.26 per share, expiring January 14, 2036. Under the company’s 2024 Equity Compensation Plan, 25% of this option vests on January 14, 2027, with the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.
Corbus Pharmaceuticals Holdings, Inc. CEO Yuval Cohen reported new equity awards. On January 14, 2026, he received 50,000 restricted stock units that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027. Following this grant, he beneficially owned 188,187 common shares, including 173,561 unvested RSUs subject to their vesting schedules. He was also granted stock options for 150,000 shares at an exercise price of $8.26, expiring January 14, 2036, with 25% vesting on January 14, 2027 and the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.
Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Operating Officer, Ian Hodgson. On January 14, 2026, he received 28,365 restricted stock units (RSUs), which will be settled in common shares. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a provision for partial accelerated vesting if his service is terminated by the company without cause after the first vesting date.
On the same date, he was also granted 85,095 stock options with a $8.26 exercise price under the 2024 Equity Compensation Plan. Twenty‑five percent of this option vests on January 14, 2027, and the remaining 75% vests in equal monthly installments over 36 months starting February 14, 2027. Following these grants, he beneficially owned 54,342 shares of common stock, which include 53,108 unvested RSUs subject to their respective vesting schedules, and 85,095 options.
Corbus Pharmaceuticals Holdings, Inc. insiders affiliated with Cormorant Asset Management reported selling 30,029 shares of common stock on 12/11/2025. The sale was coded as a disposition and executed in a series of open-market transactions at a weighted average price of $11.456 per share, with individual trade prices ranging from $11.20 to $12.15.
Following this transaction, the reporting persons indirectly beneficially owned 2,344,971 Corbus Pharmaceuticals shares. The filing states that all shares sold were held by Cormorant Global Healthcare Master Fund, LP and that each reporting person disclaims beneficial ownership beyond its or her pecuniary interest.
Corbus Pharmaceuticals (CRBP) CEO and director Yuval Cohen reported insider transactions on a Form 4. On 10/24/2025 and 10/27/2025, he exercised stock options at $4.26 per share and sold the same number of common shares under a Rule 10b5-1 trading plan adopted on March 14, 2025.
He exercised 18,660 options on 10/24 and sold 18,660 shares at a weighted average price of $17.01 (range $16.79–$17.38). He exercised 8,973 options on 10/27 and sold 8,973 shares at a weighted average price of $17.14 (range $17.00–$17.31).
Following these transactions, he beneficially owned 138,187 shares, which includes 123,561 unvested RSUs subject to vesting schedules. Remaining derivative holdings include 22,106 stock options at an exercise price of $4.26 expiring on 02/13/2033.
Corbus Pharmaceuticals (CRBP) Form 4: On 10/24/2025, the company’s Chief Financial Officer exercised stock options for 12,981 shares at $4.26 per share (Code M) and sold 12,981 common shares at a weighted average price of $17.02 (Code S) pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.
Following these transactions, the officer beneficially owns 73,313 shares; this amount includes 57,632 unvested RSUs subject to each grant’s vesting schedule. The reported sale occurred in multiple trades ranging from $16.79 to $17.38. The option award was granted under the 2014 Equity Compensation Plan, with 25% vesting on February 13, 2024 and the remainder vesting monthly over 36 months commencing on March 13, 2024.
Corbus Pharmaceuticals (CRBP) director Anne Altmeyer reported an option exercise and same‑day sale. On 10/20/2025, she exercised 1,060 stock options at $4.8 per share (code M) and sold 1,060 common shares at $20.5 (code S). After these transactions, she beneficially owned 6,191 common shares directly.
The filing notes a Rule 10b5‑1 trading plan adopted on 11/14/2024 governed the sale. It also states her holdings include 4,800 unvested RSUs granted on 05/30/2025 that vest 100% on the one‑year anniversary of grant. Following the exercise, 4,247 options remain outstanding, fully vested, at a $4.8 exercise price expiring on 09/26/2032.